Literature DB >> 17560508

Myotonic dystrophy in a female with myasthenia gravis.

María de los Angeles Avaria1, Karin Kleinsteuber, Fernando Novoa, Paola Faundez, Pilar Carvallo.   

Abstract

The likelihood of coexistence in the same patient of myasthenia gravis and myotonic dystrophy has been estimated at 1 in 40 million. The case of a patient in whom both diagnoses were made is reported here. A 13-year-old girl was diagnosed with myasthenia gravis because of weakness, fluctuating fatigability, and mild difficulty with chewing and swallowing. She had ptosis, with weakness predominantly of her face, arms, and neck. Serum antibodies against acetylcholine receptors were 9.9 nmol/L. She was started on pyridostigmine, with significant clinical improvement, reassuming normal daily activities. Two years later, generalized weakness reappeared and reappraisal of her symptomatology disclosed tongue percussion and hand action myotonia. Molecular genetic analysis disclosed 550 repeats of cytosine-thymidine-guanosine triplets on the DMPK gene. Undiagnosed relatives had expansions ranging from 110 to 1000 repeats. Myotonic dystrophy is considered the most common muscular dystrophy, with highly variable clinical manifestations; mildly affected individuals may escape clinical detection. Myasthenia gravis has an estimated prevalence of 15 per 100,000. No studies on the epidemiology of these diseases have been done in Chile. Although both diseases have specific clinical and laboratory presentations, they share some features in the mode of presentation that may generate difficulty in diagnosis of both entities in the same patient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560508     DOI: 10.1016/j.pediatrneurol.2007.01.014

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  1 in total

1.  The coexistence of myasthenia gravis and myotonic dystrophy type 2 in a single patient.

Authors:  Ana Nikolic; Vidosava Rakocevic Stojanovic; Stanka Romac; Dusanka Savic; Ivana Basta; Dragana Lavrnic
Journal:  J Clin Neurol       Date:  2013-04-04       Impact factor: 3.077

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.